Clinical Trial Update: Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update of neoadjuvant MPDL3280A (atezolizumab) with nab-paclitaxel and carboplatin in non-small cell lung cancer has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• MPDL3280A (atezolizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Columbia University | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2023-12-12